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Skin infections with Staphylococcus aureus are not only
an important cause of morbidity and even mortality,
but are thought to serve as initiation and/or persis-
tance factors for numerous in¯ammatory skin dis-
eases, including psoriasis and atopic dermatitis. One
mechanism by which S. aureus can modulate the
immune system is through the production of
proteins such as superantigenic toxins, Protein A, as
well through the cytolytic a-toxin. This review
serves to discuss the biology of these three types of
proteins, with emphasis on their ability to stimulate
the production of powerful pro-in¯ammatory lipid-
and protein-derived cytokines in keratinocytes.
Characterization of interactions between these
proteins and the keratinocyte can provide a better
understanding of how bacterial infection modulates
in¯ammatory skin diseases, as well as provide the
basis for improved therapies involving antibacterial
agents. Key words: a-toxin/keratinocytes/platelet-activat-
ing factor/protein A/Staphylococcus aureus/superanti-
gens. Journal of Investigative Dermatology Symposium
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S
kin infections with Staphylococcus aureus are an important
cause of morbidity and even mortality. Infections by these
bacteria not only cause disease directly, but are thought to
be important triggers in worsening in¯ammatory skin
diseases ranging from atopic dermatitis to psoriasis
(reviewed by Leung et al, 1998). One mechanism by which
S. aureus can accomplish this is through the production of soluble
proteins with potent immunomodulatory effects. The objective of
this review is to focus on one aspect of cutaneous S. aureus bacterial
infection; how interactions between keratinocytes and bacterial
proteins such as superantigens, a-toxin, and Protein A can
potentially affect the in¯ammatory process.
THE KERATINOCYTE AS AN ACTIVE PARTICIPANT IN
CUTANEOUS INFLAMMATION
Keratinocytes are by far the most abundant cell type in the
epidermis, and our concept of the keratinocyte's role in in¯am-
matory processes has changed greatly from a passive target to an
active participant. The keratinocyte has the ability to produce and
release numerous lipid and protein cytokines (reviewed by Greaves
and Camp, 1988; Kupper, 1990). Keratinocytes also can express
adhesion molecules that allow enhanced leukocyte interactions.
These properties, as well as the relative long life of a keratinocyte
compared with other in¯ammatory cells such as the neutrophil or
eosinophil, make the keratinocyte a potentially important player in
the cutaneous in¯ammatory response.
Keratinocyte-derived cytokines Keratinocytes have the
capacity to synthesize and release a wide variety of
immunomodulatory molecules (a partial list is found in Table I).
Keratinocyte-derived pro-in¯ammatory and immunomodulatory
molecules can be divided into those that are lipid versus those that
are protein based. Lipid-derived in¯ammatory mediators produced
by keratinocytes include derivatives of phospholipids [platelet-
activating factor (1-O-alkyl-2-acetyl glycerophosphocholine; PAF)
and lyso-phosphatidic acid (LPA)], arachidonic acid metabolites
(eicosanoids), and others including ceramides. These mediators
tend to be synthesized by keratinocytes in response to membrane
damage. Of signi®cance, essentially all of these lipid-derived
mediators are produced in response to an increased calcium
mobilization signal, which can be seen following membrane
damage.
The major eicosanoid synthesized by human keratinocytes is
PGE2, with lesser amounts of PGD2 and PGF2-a (Pentland and
Needleman, 1986). Injection of nanogram amounts of PGE2 causes
erythema in human skin (Camp and Greaves, 1987). Larger
amounts induce swelling through vasodilatory effects on blood
vessels, with only minimal leukocyte chemoattractive properties.
PGD2 also has erythrogenic effects, as well as granulocyte
chemoattractant properties (Woodward et al, 1990). Though
keratinocytes synthesize hydroxyeicosateranoic acids (HETE),
they do not synthesize signi®cant levels of leukotrienes (Greaves
and Camp, 1988).
Produced by the subsequent actions of phospholipase A2 and
PAF acetyltransferase, PAF is synthesized in response to the same
stimuli that induce eicosanoid production (Pinckard et al, 1994).
Intradermal injection of PAF results in a painful wheal and ¯are
reaction within minutes. Human keratinocytes both synthesize
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PAF as well as express functional PAF receptors (PAF-R) (Michel
et al, 1990; Travers et al, 1995). Activation of the epidermal PAF-R
results in the biosynthesis of numerous mediators, including
eicosanoids, TNF-a, IL-6, IL-8, and PAF itself (Pei et al, 1998).
Amongst the protein-derived cytokines produced by kerati-
nocytes, TNF-a and IL-1 have been termed primary cytokines
due to their ability to induce in¯ammatory reactions in part
through the ability to induce a host of other lipid and protein
mediators (Kupper, 1990). TNF-a and IL-1 both exert effects
on receptors expressed on keratinocytes that are linked to the
nuclear factor kB pathway, with resultant production of
cascades of other protein and lipid cytokines. IL-6 is a
pleiotropic cytokine with effects on both B and T cells
(Paquet and Pierard, 1996). IL-7 has the ability to stimulate the
growth of both progenitors and mature B and T cells (Heu¯er
et al, 1993). IL-8 is a potent neutrophil chemoattractant also
produced by keratinocytes. IL-12 is a potent TH1 cytokine that
promotes activation of macrophages that can be synthesized by
keratinocytes in response to varied stimuli including phorbol
esters and IFN-g (Aragane et al, 1994). In addition, bacterial
superantigens appear to induce production of skin-homing
(cutaneous lymphocyte-associated antigen-positive; CLA) T cells
through an IL-12-dependent process (Leung et al, 1995).
Though resting keratinocytes do not synthesize the T cell
activating cytokine IL-15, its production can be induced by
IFN-g, a process inhibited by dexamethasone (Han et al, 1999).
IL-18, a novel cytokine that strongly induces IFN-g production
in T cells, has also been shown to be synthesized by human
and murine keratinocytes. Hyperosmolar stress induced by
mannitol or NaCl is a potent stimulus for IL-18 production
in both epithelial and endothelial cells, suggesting that this
cytokine could be important in damage-mediated in¯ammatory
responses (Takeuchi et al, 1999). Thus, a keratinocyte that
sustains membrane damage has the potential to synthesize and
release numerous lipid and protein cytokines that could
modulate the in¯ammatory response.
Keratinocyte adhesion molecules In addition to the ability
of keratinocytes to modulate in¯ammation through soluble
mediators, these cells can also express membrane-associated
molecules that can serve to bind immune cells as well as to
stimulate signal transduction pathways leading to further
production of mediators. Through its ability to bind the B-2
integrin leukocyte function-associated antigen found on most
leukocytes, the adhesion molecule intracellular adhesion molecule-
1 (ICAM-1; CD54) is an important mediator of cellular immune
reactions (reviewed by Krutmann and Grewe, 1995). Though not
found on resting epidermal cells, ICAM-1 surface expression can be
induced by cytokines including TNF-a (Krutmann et al, 1990) and
PAF (Pei et al, 2000), as well as by physical methods including tape-
stripping (Nickoloff and Naidu, 1994). Similar to ICAM-1, resting
keratinocytes do not express the costimulatory molecule B7-1
(CD80), yet epidermal expression can be seen during allergic and
contact dermatitis (Wakem et al, 2000). The signi®cance of
epidermal B7-1 expression is not clear, though this signaling
molecule usually associated with antigen-presenting cells prevents
the induction of T cell anergy and induces IL-2 production during
antigen presentation. Of note, transgenic mice overexpressing B7-1
on keratinocytes exhibit exaggerated and persistent contact
hypersensitivity reactions to a variety of haptens (Gaspari et al,
1998).
In addition to adhesion and costimulatory molecules, keratino-
cytes can also express MHC-II molecules (i.e., HLA-DR) in
response to various pro-in¯ammatory and immune stimuli (Basham
et al, 1983). MHC-II molecules can signal through intracellular
calcium, as well as through kinases including protein kinases A and
C (PKA and PKC) (Wakita et al, 1995; Etienne et al, 1999).
Keratinocyte MHC-II molecules can also trigger the production of
cytokines such as TNF-a (Tokura et al, 1994).
BACTERIAL SUPERANTIGENS AND THE
KERATINOCYTE
The biology of superantigens The term ``superantigen'' was
®rst coined by White et al in 1989 and refers to a group of microbial
and viral proteins that differ in several important respects from
conventional peptide antigens (White et al, 1989). First, unlike
conventional protein antigens, which are taken up and processed by
antigen-presenting cells, superantigens exert their effects as globular
intact proteins. Similar to peptide antigens, superantigens are
presented by class II MHC molecules; however, they do not
interact with the MHC peptide b antigen binding groove, but
instead bind to conserved amino acid residues that are on the outer
walls of the peptide antigen-binding groove. Thus, whereas
recognition of conventional peptide antigens by the T cell
receptor is restricted by MHC alleles, recognition of
superantigens is not generally MHC restricted. Second,
superantigens primarily recognize and bind to the variable region
of the T cell receptor b chain (VB). This is in contrast to nominal
peptide antigens, which require recognition by all ®ve variable
elements (i.e., VB, DB, JB, Va, Ja) of the T cell receptor.
Therefore, the responding frequency of a superantigen is several
orders of magnitude greater than a conventional peptide antigen.
The unique ability of a superantigen to bind directly to (and
signal through) MHC class II molecules, and cross-link with a large
percentage of T cells expressing relevant T cell receptor VB chains,
provides an explanation for the potent immune stimulation seen
with these molecules (Tiedemann and Fraser, 1996). The proto-
typical disease due to bacterial superantigens is toxic shock
syndrome caused by staphylococcal exotoxins or streptococcal
enterotoxins (Deresiewicz, 1997).
Superantigens and in¯ammatory skin diseases As outlined
above, bacterial superantigens possess several properties that can
contribute to disease pathogenesis. Superantigens can bind to and
activate MHC class II molecules, whether constitutively expressed
on professional antigen presenting cells such as monocytes,
Langerhans, or dendritic cells, or on nonprofessional antigen-
presenting cells such as the keratinocyte following cytokine
stimulation. Signi®cant pathologic effects can be seen due to
either local or massive systemic release of protein cytokines as well
as other pro-in¯ammatory mediators. In addition, pro-
in¯ammatory effects would be further ampli®ed by subsequent
activation of T cells.
Of signi®cance for the ability of these proteins to induce
cutaneous in¯ammation, recent evidence suggests that super-
antigenic stimulation of T cells promotes skin homing by
upregulation of the skin homing receptor CLA, a modi®ed selectin
that promotes localization of T cells to the skin. Leung et al
reported that stimulation of peripheral blood mononuclear cells
with bacterial superantigens resulted in a signi®cant increase of
CLA+ T cells, but not T cells expressing other homing molecules,
in comparison with treatment with other agents including
phytohaemogluttinin or anti-CD3 (Leung et al, 1995). Bacterial
toxins were also found to induce IL-12 production in this model
system. Of note, induction of toxin-induced CLA expression was
blocked by anti-IL-12, and the addition of IL-12 to phytohae-
Table I. Immunomodulatory molecules produced by
keratinocytes
Lipid-derived Protein-derived
Prostaglandins E2, D2, F2-a Interleukins 1, 6, 8, 12, 15, 18
12-Hydroxyeicosatetraenoic acid Tumor necrosis factor-a
Platelet-activating factor Transforming growth factor-a
Lyso-phosphatidic acid Interferon-b
Ceramides Granulocyte and Granulocyte
macrophage colony stimulatory factors
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mogluttinin-stimulated T cells induced CLA, but not expression of
the mucosal homing receptor a e b 7-integrin (Leung et al, 1995b).
These data suggest that bacterial toxins induce the expansion of
skin-homing CLA+ T cells in an IL-12-dependent manner, and
thus may contribute to the development of skin rashes in
superantigen-mediated diseases.
Psoriasis is a chronic in¯ammatory skin disorder affecting up to
2% of the general population. The characteristic lesion of psoriasis is
a well-demarcated erythematous papule or plaque containing
hyperproliferating keratinocytes, as well as in®ltrating neutrophils,
monocytes, and T lymphocytes (Nickoloff, 1991). Though con-
sidered an autoimmune disease, considerable evidence suggests an
important role for bacteria in the pathogenesis of psoriasis.
Colonization and/or infection with Staphylococcus and Streptococcus
have been reported to exacerbate psoriasis (Henderson and Highet,
1988; Leung et al, 1993). Superantigenic toxins produced by these
bacteria have been implicated in the initiation and/or propagation
of psoriasis (reviewed by Leung et al, 1998). Indeed, a group of
psoriatics whose skin disease was worsening were found to be
secondarily infected with superantigen-expressing S. aureus, and
skin biopsies revealed lesional T cell receptor VB skewing
consistent with the pattern of the isolated superantigen (Leung et
al, 1993). Injection of superantigen-stimulated immunocytes into
normal skin from subjects with psoriasis xenografted onto an
immunode®cient mouse has also been shown to induce clinical,
histologic, and immunologic changes consistent with psoriasis
(Boehncke et al, 1996; Wrone-Smith and Nickoloff, 1996).
The most convincing clinical and experimental association
between bacterial superantigens and psoriasis, however, is in
patients with acute eruptive (guttate) psoriasis (Lewis et al, 1993;
Leung et al, 1995). Of note, Leung et al demonstrated up to 50% T
cell receptor VB2+ T cells in perilesional skin of subjects with
acute eruptive psoriasis induced by a Streptococcal pyrogenic
exotoxin C (SPEC) expressing Streptococcus (Leung et al, 1995).
Altogether, these studies have implicated bacterial superantigens in
both the initiation as well as the worsening of psoriasis.
The keratinocyte as a target for superantigens Due to the
lack of MHC II molecules, the resting keratinocyte is not thought
to be a direct target for superantigens (Ezepchuk et al, 1996);
however, treatment of resting keratinocytes with cytokines such as
g-interferon has been shown to upregulate MHC II molecules
(Basham et al, 1983). Superantigens have been shown to directly
bind to and stimulate g-interferon-treated primary cultures of
human and murine keratinocytes as well as epidermal carcinoma
cell lines (Nickoloff et al, 1993; Strange et al, 1994; Tokura et al,
1994). Early biochemical events seen as a consequence of MHC II
and superantigen interactions in keratinocytes include a transient
intracellular calcium mobilization (Wakita et al, 1995).
Superantigens have also been shown to induce the production of
TNF-a in keratinocytes in vitro (Tokura et al, 1994; Ezepchuk et al,
1996). In addition to their well-characterized effects on MHC II
molecules, superantigens have also been reported to interact with
MHC class I molecules on squamous cell carcinoma cell lines
(Haffner et al, 1996). Topical application of superantigens to atopic
skin also induces acute eczematous changes and T cell recptor VB
skewing (Skov et al, 2000)
Hyperreactivity of psoriatic keratinocytes to topical
superantigens Signi®cant evidence based on ®nding
peripheral blood or skin T cells with TCR VB skewing and the
isolation of a superantigen with a relevant TCR VB pro®le has
linked superantigens to either initiatory events in acute guttate
psoriasis (Lewis et al, 1993; Leung et al, 1995), or to worsening of
psoriasis skin disease (Leung et al, 1993). Recent studies by Travers
et al have examined the effects of topical application of nanogram
amounts of the staphylococcal superantigens ZEB and TSST-1, and
the streptococcal superantigens SPEA and SPEC to tape-abraded
skin of psoriatic patients for 48 h (Travers et al, 1999).
In¯ammatory responses to these puri®ed bacterial proteins were
seen in both normal subjects as well as in psoriatics; however,
patients with psoriasis exhibited signi®cantly increased
in¯ammatory skin responses in comparison with controls, or
subjects with atopic dermatitis or lichen planus. Reactivity of
psoriatic subjects to topical superantigens correlated with the
amount of skin disease, and was greatest in subjects who exhibited
the isomorphic (Koebner) phenomenon. Consistent with the
clinical hyperactive response, in situ hybridization studies of skin
biopsies obtained 6 and 24 h following patch testing with
superantigens demonstrated increased epidermal TNF-a mRNA
in psoriatics than controls.
Though signi®cant numbers of mononuclear cells were seen in
superantigen-induced skin reactions, surprisingly, skin biopsies
from the lesions did not reveal increased numbers of T cells
expressing the predicted T cell receptor VB type for the
superantigens. This is in contrast to the T cell receptor VB
skewing found after application of larger doses of superantigens on
the intact skin of subjects with atopic dermatitis (Skov et al, 2000).
In addition, immunohistochemical studies revealed increased
epidermal MHC-II expression in reactions in psoriatics compared
with control skin. Given that superantigens have the ability to
induce TNF-a production with MHC-II expressing keratinocytes
in vitro (Tokura et al, 1994; Ezepchuk et al, 1996), one explanation
for the increased clinical reactivity and increased epidermal TNF-a
production found in psoriatic subjects, would be that the super-
antigens were stimulating cytokine production from MHC-II
positive keratinocytes, with T cell accumulation being in response
to these keratinocyte-derived cytokines. This would also explain
the lack of T cell receptor VB skewing as well. Consistent with this
notion that epidermal MHC-II±superantigen interactions were
responsible for the enhanced skin reactions in psoriatic subjects, a
mutant TSST-1 toxin that does not bind to MHC-II (TSST-
1G31S/S32P) did not induce skin in¯ammation, even at 10-fold
higher concentrations than native superantigens (Travers et al,
1999). The lack of skin reactions to the mutant TSST-1 also suggest
that the exotoxin-induced skin responses were not due to a delayed
type hypersensitivity reaction to a conventional antigen.
The ability of superantigens to stimulate the production of
potent pro-in¯ammatory and cytotoxic cytokines such as TNF-a
in MHC-II positive keratinocytes provides an alternative mechan-
ism by which colonization or actual infection with S. aureus can
induce skin in¯ammation. This pathway could be relevant in
psoriasis, as psoriatic lesions are often colonized with
Staphylococcus and Streptococcus (Leung et al, 1993; Ezepchuk
et al, 1996), and scratching of the skin would be expected to mimic
tape-stripping, by both compromising the barrier function as well
as activating the epidermis (Nickoloff and Naidu, 1994). This
alternative mechanism may explain why some psoriatic patients
report improvement of their disease activity following treatment
with oral antibiotics (Rosenberg et al, 1986). It may also account for
several reports that fail to demonstrate selective expansion of T cell
receptor VB in the skin of patients with plaque psoriasis (Schmitt-
Egenolf et al, 1991; Boehncke et al, 1995). Thus, epicutaneous
application of superantigens on psoriatic skin may result in an acute
in¯ammatory, keratinocyte-mediated response rather than super-
antigen-mediated T cell activation.
STAPHYLOCOCCAL a-TOXIN, PROTEIN A, AND THE
KERATINOCYTE
In addition to toxins that can have profound immunomodulatory
effects through their abilities to act as superantigens, S. aureus can
produce other proteins that can act as virulence factors and affect
host responses. The production of transmembrane pores by
staphylococcal a-toxin can induce a potent cytotoxic response
that also results in cytokine production. Though not associated
with a direct cytotoxic response, staphylococcal Protein A can also
induce cytokine production in keratinocytes. In contrast to
superantigens, both a-toxin and Protein A can interact with
resting (i.e., MHC II-negative) keratinocytes.
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The biology of a-toxin Staphylococcal a-toxin is released by
bacteria as a 293 residue single chain polypeptide. Upon interaction
with a target cell, a-toxin forms a heptamer, which results in the
formation of a transmembrane pore (Song et al, 1996). Recent
studies using biotinylated a-toxin in susceptible versus resistant cells
suggest that the signaling and cytotoxic effects are related to the
ability of the a-toxin heptamer to form a transmembrane channel
(Valeva et al, 1997). Formation of transmembrane pores results in
membrane damage as well as an in¯ux of extracellular calcium, a
potent damage-related stimulus for many cells. Similar to calcium
ionophores such as A23187, small amounts of a-toxin result in
signaling and potential repairable damage, whereas larger amounts
result in cell death.
In endothelial cells as well as in PC-12 cells, a-toxin activates
PLA2 via a calcium-dependent process (Fink et al, 1989). In
endothelial cells, a-toxin stimulates arachidonic acid release, as well
as PAF biosynthesis (Suttorp et al, 1992; Grimminger et al, 1997).
Staphylococcal a-toxin has also been reported to enhance IL-6 and
G-CSF production in IL-1b-treated endothelial cell cultures
(Soderquist et al, 1998). Exposure of isolated perfused rat hearts
to a-toxin was shown to induce coronary vasoconstriction and loss
of myocardial contractility (Sibelius et al, 2000). Signi®cant levels of
thromboxane A2 were found in the perfusate following a-toxin
treatment. Of note, indomethacin, acetylsalicylic acid, and a
speci®c thromboxane receptor antagonist inhibited a-toxin effects,
demonstrating involvement of endogenous thromboxane A2 in this
model system. Thus, a-toxin can induce organ damage not only
through direct cytolytic effects, but also through the ability to
trigger cellular production of pro-in¯ammatory and cytotoxic
soluble mediators.
The keratinocyte as a target for a-toxin Staphylococcus aureus
is not only a common agent of cutaneous infections, but can also be
isolated from many patients with in¯ammatory skin diseases such as
atopic dermatitis and psoriasis. A recent study by Ezepchuk and
colleagues demonstrated that nine of 19 strains of S. aureus obtained
from clinical lesions of atopic dermatitis and psoriasis contained a-
toxin (Ezepchuk et al, 1996). Ezepchuk et al also found that
treatment of primary cultures of human keratinocytes or the
keratinocyte-derived cell line HaCaT with a-toxin resulted in
signi®cant TNF-a production. Staphyloccoccal a-toxin also
induced cytotoxic effects in keratinocytes that were more
compatible with necrosis than apoptosis (Walev et al, 1993;
Ezepchuk et al, 1996). Injection of rabbit corneas with a-toxin
has been shown to result in signi®cant tissue edema with death of
corneal epithelial cells by both necrosis and apoptosis (Moreau et al,
1997). Though a-toxin is thought to have considerable deleterious
effects, it has been suggested that a-toxin-induced keratinocyte
damage can protect against superantigen-mediated effects by
inhibiting the ability of the keratinocyte to activate T cells
(Tokura et al, 1997).
Allapatt et al recently examined the ability of a-toxin to stimulate
lipid mediator production in human carcinoma cell lines.1 Using
select ion monitoring gas chromatography mass spectrometry,
signi®cant production of PAF as well as arachidonic acid release was
found in a-toxin-treated HaCaT cells. The amount of PAF
produced in response to 10 mg per ml a-toxin was about 25% of
that seen in response to a potent ionophore such as A23187
(Travers et al, 1995). Because activation of the epidermal PAF-R
can induce arachidonic acid release (Pei et al, 1998), the potential
involvement of endogenous PAF in a-toxin-induced arachidonic
acid release was tested using a model system created by retroviral-
mediated transduction of the PAF-R-negative epithelial cell line
KB with the human PAF-R. As shown in Fig 1, a-toxin
stimulated arachidonic acid release in both control (PAF-R-
negative) KBM as well as PAF-R-positive KBP cells; however, the
amounts of arachidonic acid released by a-toxin-treated KBP cells
were signi®cantly greater than with KBM cells (Fig 1). Similarly,
pretreatment of KBP cells with 10 mM of the PAF-R antagonist
WEB 2086 partially inhibited a-toxin-induced arachidonic acid
release in KBP but not KBM cells (data not shown). These data are
compatible with the notion that a-toxin can generate both
arachidonic acid release and PAF biosynthesis through calcium-
mediated activation of PLA2, and that endogenous PAF generated
can feed forward to induce further mediator production.
Altogether, through its direct effects on keratinocyte membranes,
a-toxin can induce the synthesis of both lipid and protein
cytokines, as well as cause direct cytotoxic effects.
Figure 1. Staphylococcal a-toxin stimulates increased
arachidonic acid release in PAF-R expressing versus control
KB cells. KB cells transduced with the PAF-R (KBP) or control
retrovirus (KBM) were stimulated with 10 mg per ml puri®ed a-toxin or
vehicle for 30 min, and arachidonic acid released into the supernatant
was quantitated by gas chromatography mass spectrometry using
deuterated arachidonic acid as internal standard as previously described
(Pei et al, 1998). The data shown are mean 6 standard deviation of
arachidonic acid released from duplicate samples from a representative
experiment of four conducted.
Figure 2. Interactions between Staphylococcal proteins and the
keratinocyte. The keratinocyte has the potential to be a target for
S. aureus proteins. Enterotoxins that act as superantigens (SAg) can signal
through MHC-II molecules found on activated keratinocytes, resulting
in a calcium mobilization response as well as the production of TNF-a.
Protein A does not appear to induce a calcium mobilization response,
but is a potent inducer of keratinocyte TNF-a production through an
unknown mechanism. Through its ability to form a heptameric
transmembrane pore, a-toxin can trigger a calcium mobilization response
as well as TNF-a production.
1Allapatt C, Leung DYM, Johnson C, Clay K, Cosgrove J, Travers JB:
Acute keratinocyte damage results in the biosynthesis of the lipid mediator
platelet-activating factor. J Invest Dermatol 112:543, 1999 (abstr)
228 TRAVERS ET AL JID SYMPOSIUM PROCEEDINGS
The biology of Protein A The unique protein derived from
the cell wall structure of S. aureus termed Protein A was discovered
over 40 y ago. A characteristic property of this protein has been its
ability to bind the Fc structure of IgG, making it a valuable
laboratory reagent for the isolation and puri®cation of antibody
molecules. Over time other biologic properties of this molecule
have been elucidated. Protein A appears to have an unrivaled
diversity of biologic activities ranging from immunomodulatory
and antitumor to antifungal and antiparasitic effects (reviewed by
Silverman, 1998). Protein A has mitogenic effects through its ability
to bind to the VH sequence of the B cell receptor, and stimulates T
cells by cross-linking MHC II molecules (Berk et al, 1986; Feijo et
al, 1997). Protein A can also stimulate production of cytokines
including g-interferon and TNF-a in immunocytes as well as
hepatocyte growth factor in ®broblasts (Baroni et al, 1998; Sinha et
al, 1999).
The keratinocyte as a target for Protein A Though Protein
A is consistently produced by essentially all strains of S. aureus, little
is known about the effects of this protein on keratinocytes.
Ezepchuk and colleagues have reported that Protein A is a potent
stimulus for TNF-a production in both primary cultures of human
keratinocytes and HaCaT cells (Ezepchuk et al, 1996). The
mechanism by which Protein A exerts its effects on epithelial
cells is not known; however, the ®nding that it has potent
cytokine-producing effects on resting keratinocytes suggests that it
is not acting via cross-linking MHC II molecules.
In contrast to a-toxin, Protein A treatment is not associated with
cytotoxic effects in epithelial cells (Ezepchuk et al, 1996). In
addition, Protein A does not stimulate a calcium mobilization
response, arachidonic acid release, or PAF biosynthesis in resting
HaCaT cells (Travers, unpublished data). Given that Protein A can
interact with MHC-II molecules in lymphocytes (Berk et al, 1986;
Tiedemann and Fraser, 1996), however, it is possible that this
protein could have similar effects on intracellular calcium levels as
superantigens exert in MHC II-expressing keratinocytes.
THERAPEUTIC IMPLICATIONS OF TOXIN±
KERATINOCYTE INTERACTIONS
The skin is a primary site of S. aureus infection and colonization.
Indeed, toxins and other bacterial protein products of S. aureus are
hypothesized to act as triggers or persistence factors in several
in¯ammatory skin diseases. Thus, an understanding of the inter-
actions of these proteins with target cells has important therapeutic
implications. Though more information is available for other cell
types, especially lymphocytes, signi®cant evidence is accumulating
suggesting that the keratinocyte may be an important target for
S. aureus-derived proteins such as superantigens, a-toxin, and
Protein A. As shown in Fig 2, keratinocyte interactions with these
proteins could result in the production of potent pro-in¯ammatory
mediators such as TNF-a and PAF, as well as direct cytotoxic
effects, compromising the barrier function of the skin. The
capability of S. aureus proteins to stimulate cutaneous in¯ammation
can explain why the judicial use of antibiotics can have therapeutic
potential in the treatment strategies in some patients with
in¯ammatory diseases.
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